February 6-8, 2019
Crowne Plaza Times Square, New York City, NY, USA
The 5th annual Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, including the most up-to-date research, data and progress, to help foster collaboration across all IO stakeholders and transform the way cancer is treated.
With the support of its educational partners The Association for Cancer Immunotherapy (CIMT), the Cancer Research Institute (CRI), The Society for Immunotherapy of Cancer (SITC) and other supporters, IO360° attracts global experts and thought leaders from large pharma, biotech, investment community, academia and research organizations as part of the speaking faculty and attendees.
A 20% registration discount applies to CIMT members, using code CIMT.
First International Cancer Immunotherapy Conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) joined forces to sponsor the first International Cancer Immunotherapy Conference.
"TRANSLATING SCIENCE INTO SURVIVAL"
September 16-19, 2015
Sheraton New York Times Square Hotel
New York City
The conference abstracts are available as an online supplement to Cancer Immunology Research at http://cancerimmunolres.aacrjournals.org/content/4/1_Supplement
CIMT Endeavour 2015
3rd CIMT Endeavour Workshop - Translating cancer science into products and companies
May 12, 2015 from 7:30-12:00 at Rheingoldhalle Congress Center in Mainz, Germany
Endeavour is a CIMT activity focusing on the translation and commercialization of cancer immunotherapies and diagnostics.
The 2015 workshop allowed scientists from the cancer immunotherapy community to present their innovation to business experts and venture capital representatives with a focus on funding initiatives, viable business models and product development. Participants shared and discussed the challenges that European and American biotech companies face in early, middle and late stage development.